The End of Whac-A-Mole Compliance: A Global Approach to Anti-Corruption Actions
02 December 2014
In light of China’s significant crackdown on corruption, targeting foreign and domestic companies, it is clear that the approach most companies take to FCPA compliance will no longer suffice. Rather than jumping from jurisdiction to jurisdiction to address potential issues, companies need to implement a well-designed compliance program to ensure that they do not become targets in countries that are following China’s lead and stepping up enforcement. Learn more in “The End of Whac-A-Mole Compliance: A Global Approach to Anti-Corruption Actions,” co-authored by San Francisco Partner Aaron Murphy and Daniel Seltzer.
Reprinted with permission from the Association of Corporate Counsel, © 2014. All Rights Reserved. www.acc.com
Reprinted with permission from the Association of Corporate Counsel, © 2014. All Rights Reserved. www.acc.com
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.